HP Adhesive

Adhesive | India

IPO | 14 December 2021

Adhesive Play at Stretched Valuation

About the Company

HP Adhesive (HPA) has grown from a single product company being a multi-product adhesives player, with a PAN India presence as well as international presence. The company's brands "HP" and "Strong Weld" in PVC adhesives product category have gained increasing acceptance led by high product quality and efficient pricing. HPA is a fast-growing multi-product, multicategory consumer adhesives and sealants company. It is among the leading adhesives manufacturing players in India in the consumer segment of the industry. HPA manufactures a wide range of consumer adhesives and sealants such as PVC, CPVC and UPVC solvent cement, synthetic rubber adhesives, PVA adhesives, silicone sealant, acrylic sealant and gasket shellac among others. It has a strong business model, which is backed by a consistent expansion in product portfolio, coupled with the introduction of new product categories and SKUs to cater to the multiple end-use applications. HPA has a pan-India reach and wide distribution network of 750 distributors that cater to more than 50,000 dealers. The company has a multi-product manufacturing facility located at Narangi, Raigad (Maharashtra), which is strategically located in close proximity to Jawaharlal Nehru Port Trust (JNPT) and thus aids exports. Notably, HPA sold its products in 21 countries during FY21. The company offers its products to several industries in India like construction, woodwork, footwear, automotive among others. HPA expects to bring epoxy adhesives and spray paints to its product basket from FY22 onwards. Meanwhile, it also sells its products under few other brand names like Strong Weld, Strong Seal and Strong Fix.

Financials in Brief

HPA reported strong growth in the past couple of years on a low base. During the last decade, its revenue and PAT clocked a CAGR of 38% and 56%, respectively. Over FY19-21, the company's revenue and PAT clocked 16% and 59% CAGR, respectively, while the average RoCE stood at ~16%. HPA made payments of Rs74mn in FY20 under the Sab Ka Vishwas legacy dispute resolution and Maha VAT amnesty schemes, whereby it reported a net loss of Rs47mn. However, the company's performance picked up during FY21 with 24% YoY revenue growth at Rs1.2bn, EBITDA margin of 10.1% and PAT of Rs101mn. For FY21, solvent cement business contributed 70% of HPA's revenue, followed by silicone & other sealants at ~9%, adhesives at ~5%, and ball valves & seal tape at ~9%. For 1HFY22, the company reported a revenue of Rs705mn, while EBITDA margin declined to 7.3% and PAT stood at Rs31mn. The impact on profitability in 1HFY22 was mainly due to higher RM prices, which could not be passed on to customers.

Our View:

On FY22 annualized financials, the IPO is valued at 51.7x EV/EBITDA, 3.8x EV/sales and 64x P/E, which is lower compared to the peer group average of 62.2x EV/EBITDA, 11.2x EV/sales and 94x P/E, respectively. However, HPA's margins and return ratios are much lower compared to peers, along with its smaller business size. Moreover, HPA's brand equity is much lower compared to key peers in the Indian market. The company is likely to report decent growth in the next couple of years with huge industry-wide opportunities, though competition is inching up. While there are ample opportunities in the silicone sealants sector, rubber adhesives and PVA adhesive businesses also present a decent potential due to the strong growth seen in sprayable applications in the foam and furnishing segment. High growth of construction activities and wood-working requirements would also act as potential demand drivers. Going ahead, HPA expects to tap new product segments by leveraging its product quality and long-standing track record in the distributors network. Though the company's long-term prospects look good with a strong business model, we believe the current valuation captures all positives and leaves hardly any meaningful upside for investors with stretched valuation.

IPO Details			
Price Band (Rs)	262-274		
Face Value (Rs)	10		
Issue Open/Closing Date	15-Dec-21/17-Dec-21		
Fresh Issues (mn)	4.1		
OFS (mn)	0.5		
Total Issue (mn)	4.6		
Minimum Bid Qty. (Nos)	50		
Issue Size (Rs bn)	1.26		
QIB / HNI / Retail	7%/15%/10%		
Implied Market Cap (Rs bn)	5.0		

Object of the Issue

- Working capital requirements.
- Capex for the existing manufacturing facility in Maharashtra.
- General Corporate Purpose

Key Risk

- Expansion plans are subject to unanticipated delays in implementation and cost overruns.
- Impact of the COVID-19 pandemic on the business and operations is uncertain.
- Dependant on relationships with the distributors and the community of appliers.
- Under-utilization and inability to utilise expanded manufacturing capacities.
- Inability to comply with repayment and other covenants.

Key Financials

(Rs mn)	FY19	FY20	FY21
Revenue	874	955	1,182
EBITDA	81	45	120
EBITDA Margin (%)	9.3	4.7	10.1
Adj. PAT	40	28	101
PAT Margin (%)	4.6	2.9	8.5
EPS (Rs)	2.2	1.5	5.5
P/E (x)	126	182	50
EV/EBITDA (x)	64.5	119.5	44.6
EV/Sales (x)	6.0	5.6	4.5
Net Worth	147	25	127
RoE (%)	27.3	111.4	79.5
Gross Debt	236	341	314
Net Block	87	95	187
Net Asset Turnover (x)	10.0	10.0	6.3
Carrier DI ID			


Source: RHP

Senior Research Analyst: Vikas Jain

Contact: (022) 42157022 / 9324611393 Email : vikas.i.jain@relianceada.com



Exhibit 1: Wide Product Portfolio with Varied Applications



Source: RHP

Exhibit 2: Diversified Cutomer Base






Exhibit 3: Geographical Mix (%)




Source: RHP Source: RHP

Exhibit 4: Strategically Located Infrastructure



Source: RHP

Exhibit 5: Indian Adhesives and Sealant Industry



Source: RHP



Reliance Securities Limited (RSL), the broking arm of Reliance Capital is one of the India's leading retail broking houses. Reliance Capital is amongst India's leading and most valuable financial services companies in the private sector. Reliance Capital has interests in asset management and mutual funds, life and general insurance, commercial finance, equities and commodities broking, wealth management services, distribution of financial products, private equity, asset reconstruction, proprietary investments and other activities in financial services. The list of associates of RSL is available on the website www.reliancecapital.co.in. RSL is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014

General Disclaimers: This Research Report (hereinafter called 'Report') is prepared and distributed by RSL for information purposes only. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through RSL nor any solicitation or offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security(ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by RSL to be reliable. RSL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of RSL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report.

Risks: Trading and investment in securities are subject to market risks. There are no assurances or guarantees that the objectives of any of trading / investment in securities will be achieved. The trades/ investments referred to herein may not be suitable to all categories of traders/investors. The names of securities mentioned herein do not in any manner indicate their prospects or returns. The value of securities referred to herein may be adversely affected by the performance or otherwise of the respective issuer companies, changes in the market conditions, micro and macro factors and forces affecting capital markets like interest rate risk, credit risk, liquidity risk and reinvestment risk. Derivative products may also be affected by various risks including but not limited to counter party risk, market risk, valuation risk, liquidity risk and other risks. Besides the price of the underlying asset, volatility, tenor and interest rates may affect the pricing of derivatives.

Disclaimers in respect of jurisdiction: The possession, circulation and/or distribution of this Report may be restricted or regulated in certain jurisdictions by appropriate laws. No action has been or will be taken by RSL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. RSL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to RSL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

Disclosure of Interest: The research analysts who have prepared this Report hereby certify that the views /opinions expressed in this Report are their personal independent views/opinions in respect of the securities and their respective issuers. None of RSL, research analysts, or their relatives had any known direct /indirect material conflict of interest including any long/short position(s) in any specific security on which views/opinions have been made in this Report, during its preparation. RSL's Associates may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report. RSL, its Associates, the research analysts, or their relatives might have financial interest in the issuer company(ies) of the said securities. RSL or its Associates may have received a compensation from the said issuer company(ies) in last 12 months for the brokerage services.RSL, its Associates, the research analysts or their relatives have not received any compensation or other benefits directly or indirectly from the said issuer company(ies) or any third party in last 12 months in any respect whatsoever for preparation of this report.

The research analysts has served as an officer, director or employee of the said issuer company(ies)?: No

RSL, its Associates, the research analysts or their relatives holds ownership of 1% or more, in respect of the said issuer company(ies).?: No

Copyright: The copyright in this Report belongs exclusively to RSL. This Report shall only be read by those persons to whom it has been delivered. No reprinting, reproduction, copying, distribution of this Report in any manner whatsoever, in whole or in part, is permitted without the prior express written consent of RSL.

RSL's activities were neither suspended nor have defaulted with any stock exchange with whom RSL is registered. Further, there does not exist any material adverse order/judgments/ strictures assessed by any regulatory, government or public authority or agency or any law enforcing agency in last three years. Further, there does not exist any material enquiry of whatsoever nature instituted or pending against RSL as on the date of this Report.

Important These disclaimers, risks and other disclosures must be read in conjunction with the information / opinions / views of which they form part of.

RSL CIN: U65990MH2005PLC154052. SEBI registration no. (Stock Broker: INZ000172433, Depository Participants: CDSL IN-DP-257-2016 IN-DP-NSDL-363-2013, Research Analyst: INH0000023841- AMFI ARN No. 29889